Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14712598.2022.2012567 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association Between Biologics and Janus Kinase Inhibitors With Inflammatory Bowel Disease as Paradoxical Reactions: A Real-World Assessment.
United European Gastroenterol J
December 2024
Division of Gastroenterology and Hepatology, NHC Key Laboratory of Digestive Diseases, State Key Laboratory for Oncogenes and Related Genes, School of Medicine, Shanghai Institute of Digestive Disease, Renji Hospital, Shanghai Jiao Tong University, Shanghai, China.
Background And Objective: With limited evidence connecting paradoxical inflammatory bowel disease (paradoxical IBD) to the newest biologics and Janus kinase inhibitors, our study aims to investigate the occurrence of paradoxical IBD induced by these agents in treating other immune-mediated inflammatory diseases (IMIDs). We aim to identify associated risk signals, the primary affected population, and the risk profile changes over time.
Methods: We performed disproportionality analysis to evaluate paradoxical IBD risk signals using data from the FDA Adverse Event Reporting System.
Effectiveness and safety of combined dupilumab and risankizumab in concomitant atopic dermatitis and psoriasis.
Int J Dermatol
December 2024
Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil.
An Bras Dermatol
December 2024
Department of Dermatology, Faculdade de Medicina de ABC, São Paulo, SP, Brazil.
Background: Psoriasis, a chronic, inflammatory skin disease, requires long-term therapy. Risankizumab is a humanized immunoglobulin G1 monoclonal antibody that specifically inhibits interleukin 23 by binding to its p19 subunit.
Objective: The authors assessed the efficacy and safety of risankizumab compared with methotrexate in adults with moderate-to-severe plaque psoriasis.
Off-label dermatologic uses of IL-23 inhibitors.
J Dermatolog Treat
December 2024
Department of Dermatology, University of Illinois College of Medicine, Chicago, IL, USA.
Background: While IL-23 inhibitors, which include guselkumab, tildrakizumab, and risankizumab, are currently FDA-approved solely for the treatment of psoriasis, several other inflammatory skin conditions have been associated with elevated IL-23 levels. The purpose of this review is to summarize and interpret the literature surrounding the off-label uses of IL-23 inhibitors in dermatologic practice.
Methods: We conducted searches on PubMed and for clinical trials, observational studies, case series, and case reports assessing use of the three IL-23 inhibitors for non-psoriatic dermatologic conditions.
Biologics Use for Psoriasis during Pregnancy and Its Related Adverse Outcomes in Pregnant Women and Newborns: Findings from WHO Pharmacovigilance Study.
Int Arch Allergy Immunol
December 2024
Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, Republic of Korea.
Article Synopsis
- The study investigates the safety of various biologics used for psoriasis during pregnancy, highlighting that data on risks is lacking outside of TNF-α inhibitors.
- Using the WHO global pharmacovigilance database, researchers analyzed over 6,500 reports of pregnancy-related adverse outcomes and compared them among different biologics.
- The findings indicate that most biologics have a lower frequency of adverse pregnancy-related outcomes compared to TNF-α inhibitors, except for brodalumab, while risankizumab showed a higher incidence of abortion and stillbirth.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!